[go: up one dir, main page]

GB0823467D0 - Novel Compounds - Google Patents

Novel Compounds

Info

Publication number
GB0823467D0
GB0823467D0 GBGB0823467.6A GB0823467A GB0823467D0 GB 0823467 D0 GB0823467 D0 GB 0823467D0 GB 0823467 A GB0823467 A GB 0823467A GB 0823467 D0 GB0823467 D0 GB 0823467D0
Authority
GB
United Kingdom
Prior art keywords
novel compounds
novel
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB0823467.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB0823467.6A priority Critical patent/GB0823467D0/en
Publication of GB0823467D0 publication Critical patent/GB0823467D0/en
Priority to JP2011542804A priority patent/JP2012513442A/en
Priority to US13/141,388 priority patent/US20110257198A1/en
Priority to PCT/EP2009/067658 priority patent/WO2010072722A1/en
Priority to CN2009801572753A priority patent/CN102325770A/en
Priority to BRPI0922904A priority patent/BRPI0922904A2/en
Priority to CA2748294A priority patent/CA2748294A1/en
Priority to KR1020117014374A priority patent/KR20110096129A/en
Priority to MX2011006768A priority patent/MX2011006768A/en
Priority to SG2011035516A priority patent/SG171745A1/en
Priority to AU2009331601A priority patent/AU2009331601A1/en
Priority to EA201170884A priority patent/EA201170884A1/en
Priority to EP09795991A priority patent/EP2379550A1/en
Priority to IL213345A priority patent/IL213345A0/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GBGB0823467.6A 2008-12-23 2008-12-23 Novel Compounds Pending GB0823467D0 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
GBGB0823467.6A GB0823467D0 (en) 2008-12-23 2008-12-23 Novel Compounds
EP09795991A EP2379550A1 (en) 2008-12-23 2009-12-21 Piperidine derivatives useful as orexin antagonists
CA2748294A CA2748294A1 (en) 2008-12-23 2009-12-21 Piperidine derivatives useful as orexin antagonists
MX2011006768A MX2011006768A (en) 2008-12-23 2009-12-21 Piperidine derivatives useful as orexin antagonists.
PCT/EP2009/067658 WO2010072722A1 (en) 2008-12-23 2009-12-21 Piperidine derivatives useful as orexin antagonists
CN2009801572753A CN102325770A (en) 2008-12-23 2009-12-21 Piperidine derivatives useful as orexin antagonists
BRPI0922904A BRPI0922904A2 (en) 2008-12-23 2009-12-21 "compounds"
JP2011542804A JP2012513442A (en) 2008-12-23 2009-12-21 Piperidine derivatives useful as orexin antagonists
KR1020117014374A KR20110096129A (en) 2008-12-23 2009-12-21 Piperidine Derivatives Useful as Orexin Antagonists
US13/141,388 US20110257198A1 (en) 2008-12-23 2009-12-21 Piperidine derivatives useful as orexin antagonists
SG2011035516A SG171745A1 (en) 2008-12-23 2009-12-21 Piperidine derivatives useful as orexin antagonists
AU2009331601A AU2009331601A1 (en) 2008-12-23 2009-12-21 Piperidine derivatives useful as orexin antagonists
EA201170884A EA201170884A1 (en) 2008-12-23 2009-12-21 DERIVATIVES OF PIPERIDINE, SUITABLE AS ANTAGONISTS OF OREXIN
IL213345A IL213345A0 (en) 2008-12-23 2011-06-02 Piperidine derivatives useful as orexin antagonists

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0823467.6A GB0823467D0 (en) 2008-12-23 2008-12-23 Novel Compounds

Publications (1)

Publication Number Publication Date
GB0823467D0 true GB0823467D0 (en) 2009-01-28

Family

ID=40344131

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0823467.6A Pending GB0823467D0 (en) 2008-12-23 2008-12-23 Novel Compounds

Country Status (14)

Country Link
US (1) US20110257198A1 (en)
EP (1) EP2379550A1 (en)
JP (1) JP2012513442A (en)
KR (1) KR20110096129A (en)
CN (1) CN102325770A (en)
AU (1) AU2009331601A1 (en)
BR (1) BRPI0922904A2 (en)
CA (1) CA2748294A1 (en)
EA (1) EA201170884A1 (en)
GB (1) GB0823467D0 (en)
IL (1) IL213345A0 (en)
MX (1) MX2011006768A (en)
SG (1) SG171745A1 (en)
WO (1) WO2010072722A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101480279B1 (en) * 2007-05-23 2015-01-09 머크 샤프 앤드 돔 코포레이션 Pyridyl piperidine orexin receptor antagonists
US8129384B2 (en) 2008-10-09 2012-03-06 Glaxo Group Limited Imidazo[1,2-a]pyrazines as orexin receptor antagonists
WO2010048010A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
AU2009307915A1 (en) * 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
JP5847087B2 (en) 2009-10-23 2016-01-20 ヤンセン ファーマシューティカ エヌ．ベー． Fused heterocyclic compounds as orexin receptor modulators
JP5848251B2 (en) 2009-10-23 2016-01-27 ヤンセン ファーマシューティカ エヌ．ベー． Fused heterocyclic compounds as orexin receptor modulators
US8653263B2 (en) 2009-10-23 2014-02-18 Janssen Pharmaceutica Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
WO2012085852A1 (en) 2010-12-22 2012-06-28 Actelion Pharmaceuticals Ltd 3,8-diaza-bicyclo[4.2.0]oct-8-yl amides
US9586962B2 (en) 2011-04-20 2017-03-07 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators
WO2013050938A1 (en) 2011-10-04 2013-04-11 Actelion Pharmaceuticals Ltd 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives
AR088352A1 (en) 2011-10-19 2014-05-28 Merck Sharp & Dohme ANTAGONISTS OF THE RECEIVER OF 2-PIRIDILOXI-4-NITRILE OREXINE
RU2014136339A (en) 2012-02-07 2016-03-27 Иолас Терапьютикс, Инк. SUBSTITUTED PROLINES / PIPERIDINES AS AN OXEX RECEPTOR ANTAGONISTS
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
TWI510481B (en) 2012-06-04 2015-12-01 Actelion Pharmaceuticals Ltd Benzimidazole proline derivative
EA201500399A1 (en) 2012-10-10 2015-09-30 Актелион Фармасьютиклз Лтд. OREXIN RECEPTOR ANTAGONISTS, WHICH ARE REPRESENTING DERIVATIVES OF [ORTO-BI- (HETERO) ARYL] - [2- (META-BI- (HETERO) ARYL) PYRROLIDIN-1-IL] METHANON
EP2970241A1 (en) 2013-03-12 2016-01-20 Actelion Pharmaceuticals Ltd. Azetidine amide derivatives as orexin receptor antagonists
ES2651475T3 (en) * 2013-12-03 2018-01-26 Idorsia Pharmaceuticals Ltd Crystalline form of (S) - (2- (6-chloro-7-methyl-1H-benzo [d] imidazol-2-yl) -2-methylpyrrolidin-1-yl) (5-methoxy-2- (2H- 1,2,3-triazol-2-yl) phenyl) methanone and its use as orexin receptor antagonists
UA119151C2 (en) * 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1 h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
AU2014358766B2 (en) 2013-12-04 2019-01-17 Idorsia Pharmaceuticals Ltd Use of benzimidazole-proline derivatives
CN103664759A (en) * 2013-12-06 2014-03-26 常熟市联创化学有限公司 Preparation method of 3-hydroxy-2-nitropyridine
AR101558A1 (en) 2014-08-13 2016-12-28 Eolas Therapeutics Inc DIFLUOROPIRROLIDINS AS MODULATORS OF THE OREXINE RECEIVER
WO2016086357A1 (en) * 2014-12-02 2016-06-09 Merck Sharp & Dohme Corp. Methyl oxazole orexin receptor antagonists
CN106749269B (en) 2015-11-23 2019-01-04 广东东阳光药业有限公司 Octahydro pyrrolo- [3,4-c] azole derivatives and application thereof
RS63471B1 (en) 2016-02-12 2022-08-31 Astrazeneca Ab Halo-substituted piperidines as orexin receptor modulators
NZ785827A (en) 2016-03-10 2025-05-02 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists
GB201702174D0 (en) 2017-02-09 2017-03-29 Benevolentai Bio Ltd Orexin receptor antagonists
GB201707499D0 (en) 2017-05-10 2017-06-21 Benevolentai Bio Ltd Orexin receptor antagonists
GB201707504D0 (en) 2017-05-10 2017-06-21 Benevolentai Bio Ltd Orexin receptor antagonists
WO2020007964A1 (en) 2018-07-05 2020-01-09 Idorsia Pharmaceuticals Ltd 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives
WO2020099511A1 (en) 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Benzimidazole-2-methyl-morpholine derivatives
EP4262788A4 (en) * 2020-12-16 2024-10-30 Merck Sharp & Dohme LLC OREXIN UREA RECEPTOR AGONISTS
TW202400149A (en) 2022-05-13 2024-01-01 瑞士商愛杜西亞製藥有限公司 Thiazoloaryl-methyl substituted cyclic hydrazine-n-carboxamide derivatives
CN119285532B (en) * 2024-09-24 2025-05-09 深圳市第二人民医院(深圳市转化医学研究院) A method for synthesizing N-Boc protected L-beta-homopipecolic acid methyl ester

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462856A (en) 1990-07-19 1995-10-31 Bunsen Rush Laboratories, Inc. Methods for identifying chemicals that act as agonists or antagonists for receptors and other proteins involved in signal transduction via pathways that utilize G-proteins
EP0828751A4 (en) 1995-05-05 1999-01-20 Human Genome Sciences Inc Human neuropeptide receptor
US6309854B1 (en) 1996-12-17 2001-10-30 Smithkline Beecham Corporation Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72
US6020157A (en) 1997-04-30 2000-02-01 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72X receptor
US5935814A (en) 1997-04-30 1999-08-10 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72Y receptor
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
AR016817A1 (en) 1997-08-14 2001-08-01 Smithkline Beecham Plc DERIVATIVES OF FENILUREA OR FENILTIOUREA, PROCEDURE FOR PREPARATION, COLLECTION OF COMPOUNDS, INTERMEDIARY COMPOUNDS, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT AND USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
US6372757B1 (en) 1998-05-08 2002-04-16 Smithkline Beecham P.L.C. Phenylurea and phenylthio urea derivatives
EP1289955B1 (en) 2000-06-16 2005-04-13 Smithkline Beecham Plc Piperidines for use as orexin receptor antagonists
AU2002224885A1 (en) 2000-11-28 2002-06-11 Smithkline Beecham Plc Morpholine derivatives as antagonists of orexin receptors
WO2002089800A2 (en) 2001-05-05 2002-11-14 Smithkline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
CA2451464A1 (en) 2001-06-28 2003-01-09 Smithkline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0124463D0 (en) 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0126292D0 (en) 2001-11-01 2002-01-02 Smithkline Beecham Plc Compounds
GB0127145D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Compounds
SI1751111T1 (en) 2004-03-01 2015-04-30 Actelion Pharmaceuticals Ltd. Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
TW200823227A (en) 2006-09-29 2008-06-01 Actelion Pharmaceuticals Ltd 3-aza-bicyclo[3.1.0]hexane derivatives
US20120095034A1 (en) 2007-07-03 2012-04-19 Giuseppe Alvaro Piperidine derivatives useful as orexin receptor antagonists
GB0712888D0 (en) 2007-07-03 2007-08-15 Glaxo Group Ltd Novel compounds
GB0806536D0 (en) 2008-04-10 2008-05-14 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
EA201170884A1 (en) 2012-02-28
MX2011006768A (en) 2011-07-20
WO2010072722A1 (en) 2010-07-01
CN102325770A (en) 2012-01-18
CA2748294A1 (en) 2010-07-01
AU2009331601A1 (en) 2011-06-30
KR20110096129A (en) 2011-08-29
EP2379550A1 (en) 2011-10-26
JP2012513442A (en) 2012-06-14
SG171745A1 (en) 2011-07-28
BRPI0922904A2 (en) 2018-05-29
IL213345A0 (en) 2011-07-31
US20110257198A1 (en) 2011-10-20

Similar Documents

Publication Publication Date Title
GB0823467D0 (en) Novel Compounds
GB0806536D0 (en) Novel compounds
GB0800035D0 (en) Compounds
GB0813142D0 (en) Novel compounds
GB0808747D0 (en) Novel compounds
GB0811587D0 (en) Novel Compounds
IL212799A0 (en) Novel compounds
GB0812849D0 (en) Novel compounds
GB0804592D0 (en) Novel compounds
GB0810981D0 (en) Novel compounds
GB0810228D0 (en) Novel compounds
IL213032A0 (en) Novel compounds
GB0813144D0 (en) Novel compounds
GB0808030D0 (en) Novel compounds
GB0804326D0 (en) Novel compounds
GB0800411D0 (en) Novel compounds
GB0809479D0 (en) Novel compounds
GB0804585D0 (en) Novel compounds
GB0804414D0 (en) Novel compounds
GB0806289D0 (en) Novel compounds
GB0802677D0 (en) Novel compounds
GB0822609D0 (en) Novel compounds
GB0821169D0 (en) Novel compounds
GB0819609D0 (en) Novel compounds
GB0800839D0 (en) Novel compounds